This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Cyberonics treatment rejected

US Centers for Medicare and Medicaid Services announced that it didn’t see a clear benefit from the Cyberonics Vagus Nerve Stimulator for treating depression. The announcement makes it highly unlikely that Medicare would pay for the treatment.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

The Cyberonics device is implanted in the chest and transmits electric signals to nerves in the neck. Medicare already pays for its use to treat epilepsy but a decision to reimburse it for its treatment of depression would have been a windfall for the Houston-based company.